Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies

Washington University School of Medicine36 enrolled

Overview

This study seeks to achieve two aims: * To assess the implementation of Noona software for continuous symptom monitoring for a diverse population of patients with thoracic malignancies who are undergoing radiation and * To validate remote collection of standardized PRO measures using Noona software.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Symptom Monitoring Radiation Therapy

Interventions

Noona SoftwareOTHER

Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Biopsy confirmed cancer. Radiographically apparent (i.e. not histologically or cytologically confirmed) malignancy of the thorax is allowed. * Currently planning to receive radiotherapy with or without chemotherapy for greater than one fraction. * Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). * Age 18 years or older Exclusion Criteria: -Unable to reliably access and use a device compatible with Noona software.

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Percentage of invited symptom reports completed during the study period

Time frame: Treatment through 90 days of follow-up (estimated to be 5 months)

Percentage of questions completed within each invited symptom report

Time frame: Treatment through 90 days of follow-up (estimated to be 5 months)

Secondary Outcomes

Patient reported outcomes as measured by EORTC QLQ-C30

It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Patients respond on a four-point scale from "not at all" to "very much" for most items. Most items use a "past week" recall period. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden.

Time frame: Baseline, within 1 week of completing therapy and at 90-day follow-up

Patient reported outcomes as measured by NCCN Distress Thermometer

Measures distress experienced during the past week. 10 = extreme distress and 0=no distress

Time frame: Baseline, within 1 week of completing therapy and at 90-day follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.